1 not yet recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Marc Donath: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anakinra for the Treatment of Postprandial Hypoglycemia in a Patient With Total Gastrectomy and End-Stage Renal Disease Anakinra (interleukin-1 receptor antagonist), Placebo Comparator (0.9% NaCl) - Postprandial Hypoglycemia, End-stage Renal Disease (ESRD) | Phase 2 | Not yet recruiting | Marc Donath | 1 | 2026-07-01 | 2026-05-12 |
| Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia Dapansutrile, Placebo - Diabetes Mellitus, Type 2 | Phase 2 | Recruiting | Marc Donath | 300 | 2024-07-09 | 2026-02-25 |
Diabetes Mellitus, Type 2 (1) · Glucose Metabolism Disorders (1) · Hypoglycemia (1) · Inflammation (1) · Kidney Failure, Chronic (1)
Interleukin 1 Receptor Antagonist Protein (1) · Receptors, Interleukin-6 (1) · dapansutrile (1)
Switzerland (2) · Belgium (1) · France (1) · Germany (1)
Marc Y. Donath, Prof. (1) · Matthias Hepprich, PD Dr. med. (1)
2023 (1), 2025 (1)